The U.S. Supreme Court has declined to hear CareDx’s appeal in a false-advertising dispute against Natera, Inc., effectively ending the company’s quest for legal relief. This decision upholds lower-court rulings that denied CareDx damages over kidney transplant test claims.
Subscribe
Breaking News
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute
Photo by Insider Trading
Key Takeaways:
- The Supreme Court declined to consider CareDx’s false-advertising appeal
- Natera, Inc. faced allegations involving kidney transplant test claims
- Lower-court rulings denying CareDx damages remain intact
- Reuters broke the news of the justices’ decision on June 1
- The outcome underscores the legal finality of the dispute
Legal Dispute Over Kidney Transplant Tests
In a legal fight that drew attention from observers of the healthcare sector, CareDx accused Natera, Inc. of false advertising related to kidney transplant tests. These tests, central to patient care, became the core of the allegations over claims CareDx believed were misleading.
Supreme Court Decision
On June 1, Reuters reported that the Supreme Court refused to hear CareDx’s appeal. By declining the case, the justices effectively upheld rulings from lower courts. Those rulings had earlier dismissed CareDx’s arguments, denying any damages tied to the allegations.
Impact on Both Companies
For Natera, Inc., which has been listed among the best healthcare stocks, the Supreme Court’s decision provides a final closure in its favor. Meanwhile, CareDx is left with no legal recourse at the nation’s highest court, effectively ending any ongoing litigation over these particular false-advertising claims.
Industry Observations
The dispute highlights the complexity of advertising and claims in the healthcare industry, particularly when it involves cutting-edge tests for critical procedures such as kidney transplants. While the Supreme Court’s refusal to review the case brings legal certainty, it also underscores the high bar that must be met for a case to advance to the top judicial level.
Final Thoughts
With the Supreme Court’s denial in place, the lawsuit concludes, leaving in place the lower courts’ findings. This resolution marks the end of one of the more closely watched legal battles in the healthcare sector, demonstrating that advertising claims for medical tests continue to face scrutiny under U.S. law.
